Esperion Therapeutics Inc. (ESPR) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP) Comparing side by side

Since Esperion Therapeutics Inc. (NASDAQ:ESPR) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Esperion Therapeutics Inc. 145.42M 9.10 68.30M -7.54 0.00
ANI Pharmaceuticals Inc. 207.98M 4.08 13.54M 1.30 53.14

Table 1 demonstrates Esperion Therapeutics Inc. and ANI Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Esperion Therapeutics Inc. -46.97% -48.6% -35.7%
ANI Pharmaceuticals Inc. 6.51% 0.2% 0.1%

Risk & Volatility

Esperion Therapeutics Inc. is 98.00% more volatile than Standard & Poor’s 500 because the stock has a beta of 1.98. In other hand, ANI Pharmaceuticals Inc. has beta of 2.33 which is 133.00% more volatile than Standard & Poor’s 500.

Liquidity

Esperion Therapeutics Inc. has a Current Ratio of 3.9 and a Quick Ratio of 3.9. Competitively, ANI Pharmaceuticals Inc.’s Current Ratio is 0.9 and has 0.7 Quick Ratio. Esperion Therapeutics Inc.’s better ability to pay short and long-term obligations than ANI Pharmaceuticals Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for Esperion Therapeutics Inc. and ANI Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Esperion Therapeutics Inc. 0 3 3 2.50
ANI Pharmaceuticals Inc. 0 0 3 3.00

Esperion Therapeutics Inc.’s average target price is $69.17, while its potential upside is 40.68%. Meanwhile, ANI Pharmaceuticals Inc.’s average target price is $75, while its potential upside is 6.32%. The data from earlier shows that analysts opinion suggest that Esperion Therapeutics Inc. seems more appealing than ANI Pharmaceuticals Inc.

Institutional & Insider Ownership

Roughly 0% of Esperion Therapeutics Inc. shares are owned by institutional investors while 82.7% of ANI Pharmaceuticals Inc. are owned by institutional investors. 2.4% are Esperion Therapeutics Inc.’s share owned by insiders. Competitively, insiders own roughly 3.7% of ANI Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Esperion Therapeutics Inc. -2.95% 17.72% 5.18% -10.13% 19.79% 6.46%
ANI Pharmaceuticals Inc. -2.62% 1.01% 17.95% 31.3% 12.75% 53.58%

For the past year Esperion Therapeutics Inc.’s stock price has smaller growth than ANI Pharmaceuticals Inc.

Summary

ANI Pharmaceuticals Inc. beats Esperion Therapeutics Inc. on 10 of the 13 factors.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.